Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus

Repository of Nicolaus Copernicus University

Show simple item record

dc.contributor.author Navarese, Eliano Pio
dc.contributor.author Buffon, Antonino
dc.contributor.author Andreotti, Felicita
dc.contributor.author Koziński, Marek
dc.contributor.author Welton, Nicky
dc.contributor.author Fabiszak, Tomasz
dc.contributor.author Caputo, Salvatore
dc.contributor.author Grześk, Grzegorz
dc.contributor.author Kubica, Aldona
dc.contributor.author Świątkiewicz, Iwona
dc.contributor.author Sukiennik, Adam
dc.contributor.author Kelm, Malte
dc.contributor.author De Servi, Stefano
dc.contributor.author Kubica, Jacek
dc.date.accessioned 2013-04-17T12:14:27Z
dc.date.available 2013-04-17T12:14:27Z
dc.date.issued 2013-04-17
dc.identifier.citation American Journal of Cardiology, vol. 111, 8, 2013, pp. 1123-1130
dc.identifier.issn 0002-9149
dc.identifier.uri http://repozytorium.umk.pl/handle/item/492
dc.description.abstract Recent reports indicate that statins are associated with an increased risk for new-onset diabetes mellitus (DM) compared with placebo and that this relation is dose dependent. The aim of this study was to perform a comprehensive network meta-analysis of randomized controlled trials (RCTs) investigating the impact of different types and doses of statins on new-onset DM. RCTs comparing different types and doses of statins with placebo were searched for using the MEDLINE, Embase, and Cochrane databases. A search of RCTs pertinent to this meta-analysis covering the period from November 1994 to October 2012 was conducted by 2 independent investigators using the MEDLINE, Cochrane, Google Scholar, and Embase databases as well as abstracts and presentations from major cardiovascular meetings. Seventeen RCTs reporting the incidence of new-onset DM during statin treatment and including a total of 113,394 patients were identified. The RCTs compared either a statin versus placebo or high-dose versus moderate-dose statin therapy. Among different statins, pravastatin 40 mg/day was associated with the lowest risk for new-onset DM compared with placebo (odds ratio 1.07, 95% credible interval 0.86 to 1.30). Conversely, rosuvastatin 20 mg/day was numerically associated with 25% increased risk for DM compared with placebo (odds ratio 1.25, 95% credible interval 0.82 to 1.90). The impact on DM appeared to be intermediate with atorvastatin 80 mg/day compared with placebo (odds ratio 1.15, 95% credible interval 0.90 to 1.50). These findings were replicated at moderate doses. In conclusion, different types and doses of statins show different potential to increase the incidence of DM. 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:1123e1130)
dc.language.iso eng
dc.rights info:eu-repo/semantics/openAccess
dc.subject Meta-analysis
dc.subject Statin
dc.subject Diabetes Mellitus
dc.title Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus
dc.type info:eu-repo/semantics/article

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search repository

Advanced Search


My Account